What is a stock summary page? Click here for an overview.
Business Description
Helix BioPharma Corp
NAICS : 325412
SIC : 3741
ISIN : CA4229101098
Description
Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidate is L-DOS47 for Tumor Defence Breaker is in clinical trials for pancreatic cancer.
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | -0.01 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -45.3 | |||||
3-Year EPS without NRI Growth Rate | -43.9 | |||||
3-Year FCF Growth Rate | -20.4 | |||||
3-Year Book Growth Rate | 65.6 |
Momentum Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
9-Day RSI | 3.52 | |||||
14-Day RSI | 4.55 | |||||
6-1 Month Momentum % | -50.25 | |||||
12-1 Month Momentum % | -33.93 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.99 | |||||
Quick Ratio | 0.99 | |||||
Cash Ratio | 0.88 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -20.2 | |||||
Shareholder Yield % | -13.01 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROA % | -871.49 | |||||
ROIC % | -28488.57 | |||||
3-Year ROIIC % | 5.24 | |||||
ROC (Joel Greenblatt) % | -39252 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
EV-to-EBIT | -4.12 | |||||
EV-to-EBITDA | -4.12 | |||||
EV-to-FCF | -11 | |||||
Earnings Yield (Greenblatt) % | -24.27 | |||||
FCF Yield % | -8.66 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:HBPCF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Helix BioPharma Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | |||
EPS (TTM) ($) | -0.323 | ||
Beta | 0.12 | ||
3-Year Sharpe Ratio | -0.88 | ||
3-Year Sortino Ratio | -0.96 | ||
Volatility % | 53.48 | ||
14-Day RSI | 4.55 | ||
14-Day ATR ($) | 0.000024 | ||
20-Day SMA ($) | 0.4549 | ||
12-1 Month Momentum % | -33.93 | ||
52-Week Range ($) | 0.4549 - 0.9169 | ||
Shares Outstanding (Mil) | 53.02 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Helix BioPharma Corp Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Helix BioPharma Corp Stock Events
Event | Date | Price ($) | ||
---|---|---|---|---|
No Event Data |
Helix BioPharma Corp Frequently Asked Questions
What is Helix BioPharma Corp(HBPCF)'s stock price today?
The current price of HBPCF is $0.45. The 52 week high of HBPCF is $0.92 and 52 week low is $0.45.
When is next earnings date of Helix BioPharma Corp(HBPCF)?
The next earnings date of Helix BioPharma Corp(HBPCF) is .
Does Helix BioPharma Corp(HBPCF) pay dividends? If so, how much?
Helix BioPharma Corp(HBPCF) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |